William Blair analyst Raju Prasad attributes the selloff yesterday in shares of Global Blood Therapeutics to a STAT report that discussed the risks associated with the company's regulatory strategy for voxelotor based on the novel hemoglobin endpoint. While the analyst agrees that there is some inherent risk to the company's approach, he also believes there is a "high likelihood" that Global Blood and the FDA will reach an agreement on a new drug application composition for an accelerated approval pathway. As such, Prasad believes the shares hold a positive risk/reward profile ahead of the company's regulatory strategy update and data presentation expected by the end of the year. He keeps an Outperform rating on Global Blood Therapeutics.